Latest Period
Q1 2026
Security Snapshot
Immix Biopharma, Inc. - Common Stock (IMMX) Institutional Ownership
CUSIP: 45258H106
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
76
Shares (Excl. Options)
27,077,219
Price
$9.11
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- IMMX on Nasdaq
- Shares outstanding
- 52,769,253
- Price per share
- $9.53
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 27,077,219
- Total reported value
- $246,615,159
- % of total 13F portfolios
- 0%
- Share change
- +1,770,592
- Value change
- +$26,862,251
- Number of holders
- 76
- Price from insider filings
- $9.53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- IMMX - Immix Biopharma, Inc. - Common Stock is tracked under CUSIP 45258H106.
- 76 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 67 to 76 between Q4 2025 and Q1 2026.
- Reported value moved from $127,497,003 to $246,615,159.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 76 institutions filings for Q1 2026.
Security key
45258H106
Latest holder period
Q1 2026
13F holders
76
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
IMMX full holder history
Immix Biopharma, Inc. SEC filings
Immix Biopharma, Inc. company facts
Immix Biopharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45258H106:
Significant Owners of Immix Biopharma, Inc. - Common Stock (IMMX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 9.1% | +24% | $46,531,399 | +$8,531,405 | 4,802,002 | +22% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| Saturn V Capital Management LP | 7% | $17,987,759 | 3,693,585 | Saturn V Capital Management LP | 26 Dec 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 3.3% | -40% | $16,959,438 | -$10,291,071 | 1,750,200 | -38% | Millennium Management LLC | 31 Mar 2026 |
As of 31 Mar 2026, 76 institutional investors reported holding 27,077,219 shares of Immix Biopharma, Inc. - Common Stock (IMMX). This represents 51% of the company’s total 52,769,253 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Immix Biopharma, Inc. - Common Stock (IMMX) together control 48% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 9.1% | 4,802,002 | +22% | 0.02% | $43,698,218 |
| Saturn V Capital Management LP | 7% | 3,693,585 | +23% | 6.1% | $33,648,559 |
| EVENTIDE ASSET MANAGEMENT, LLC | 4.8% | 2,549,019 | 0% | 0.38% | $23,221,563 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 1,787,994 | 0% | 0% | $16,288,625 |
| MILLENNIUM MANAGEMENT LLC | 3.3% | 1,750,200 | +5.4% | 0.01% | $15,944,322 |
| MARSHALL WACE, LLP | 3.1% | 1,641,552 | -17% | 0.02% | $14,954,538 |
| Logos Global Management LP | 2.3% | 1,225,000 | +22% | 0.57% | $11,159,750 |
| Bleichroeder LP | 1.9% | 1,000,000 | 0% | 1.6% | $9,110,000 |
| FRANKLIN RESOURCES INC | 1.8% | 969,066 | -1.2% | 0% | $8,828,191 |
| Velan Capital Investment Management LP | 1.4% | 740,000 | +2014% | 4.2% | $6,741,400 |
| Blue Owl Capital Holdings LP | 1% | 547,552 | -44% | 1.3% | $4,988,199 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.89% | 471,394 | +20% | 0.01% | $4,294,399 |
| BlackRock, Inc. | 0.89% | 468,377 | +260% | 0% | $4,266,915 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.88% | 463,384 | +88% | 0% | $4,223,719 |
| LGT Fund Management Co Ltd. | 0.79% | 416,594 | +233% | 0.16% | $3,795,171 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.79% | 415,001 | 0% | $3,781,000 | |
| GREAT POINT PARTNERS LLC | 0.66% | 350,000 | 0.78% | $3,188,500 | |
| Institute for Wealth Management, LLC. | 0.64% | 337,552 | 0.33% | $3,075,099 | |
| Burkehill Global Management, LP | 0.56% | 294,118 | 0% | 0.13% | $2,679,415 |
| VANGUARD FIDUCIARY TRUST CO | 0.48% | 252,914 | 0% | 0% | $2,304,047 |
| KVP Capital Advisors, LP | 0.44% | 230,423 | 0% | 1.6% | $2,099,154 |
| J. Goldman & Co LP | 0.43% | 228,089 | +93% | 0.1% | $2,077,891 |
| STATE STREET CORP | 0.36% | 191,910 | +97% | 0% | $1,748,300 |
| Qube Research & Technologies Ltd | 0.36% | 187,675 | +277% | 0% | $1,709,719 |
| SEI INVESTMENTS CO | 0.28% | 147,140 | +100% | 0% | $1,340,445 |
Institutional Holders of Immix Biopharma, Inc. - Common Stock (IMMX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 27,077,219 | $246,615,159 | +$26,862,251 | $9.11 | 76 |
| 2025 Q4 | 24,382,712 | $127,497,003 | +$111,804,992 | $5.23 | 67 |
| 2025 Q3 | 2,765,928 | $5,781,309 | +$912,474 | $2.09 | 31 |
| 2025 Q2 | 2,262,228 | $4,682,595 | -$1,044,152 | $2.07 | 23 |
| 2025 Q1 | 2,918,442 | $4,902,496 | +$70,569 | $1.68 | 22 |
| 2024 Q4 | 2,870,949 | $6,315,600 | -$1,857,745 | $2.20 | 22 |
| 2024 Q3 | 4,094,667 | $6,102,781 | -$618,016 | $1.49 | 25 |
| 2024 Q2 | 4,429,414 | $8,774,511 | -$597,024 | $1.98 | 29 |
| 2024 Q1 | 5,090,000 | $15,715,858 | +$12,671,335 | $3.07 | 34 |
| 2023 Q4 | 783,068 | $5,326,329 | +$2,756,459 | $6.92 | 28 |
| 2023 Q3 | 405,051 | $1,385,659 | -$652,595 | $3.42 | 16 |
| 2023 Q2 | 633,819 | $1,705,059 | +$653,633 | $2.69 | 17 |
| 2023 Q1 | 400,796 | $729,846 | -$97,971 | $1.82 | 12 |
| 2022 Q4 | 440,750 | $1,011,250 | +$306,049 | $2.29 | 18 |
| 2022 Q3 | 298,959 | $406,000 | +$156,569 | $1.36 | 7 |
| 2022 Q2 | 183,385 | $475,000 | +$120,000 | $2.59 | 6 |
| 2022 Q1 | 146,485 | $352,000 | -$5,019,402 | $2.39 | 7 |
| 2021 Q4 | 1,538,439 | $5,473,200 | +$3,457,200 | $3.56 | 11 |